Skip to the reference

Reference desk / Entry

Cagrilintide

Read the scope first. Then use the note and questions to examine what the evidence can answer.

Scoped product status
Investigational
Evidence label
Randomized evidence
Status as of

Reference fields

References for these fields are listed together in Sources.

Product and use scope
Investigational; no FDA-approved product.
Route context
Studied as a subcutaneous injection.
Mechanism
A long-acting amylin analogue.
Evidence
A randomized weight-management trial was funded by Novo Nordisk.
Limitations
Combination results cannot be assigned to a single ingredient.
Safety
The trial reported gastrointestinal and injection-site reactions.

A question worth making clear

Read a fraction by describing who or what is allowed into its denominator. Is the report counting people, observations, or occasions when something could be recorded? Check the inclusion rule before interpreting the numerator. If the same person could contribute more than once, ask how that affects the question the fraction answers. Also identify whether the denominator refers to the group initially considered or the records available for a particular calculation. Agreeing on the counted unit gives readers a practical way to discuss a percentage without quietly substituting a different group.

  1. Who or what qualifies for inclusion in the denominator of this result?
  2. Could one person contribute several records, and how would that change our interpretation?
  3. Does the denominator describe the initial group or the records used in this calculation?

Sources

Each date below belongs to the supplied source record. The references support the entry as a group.

  • Lau

    PubMed · Checked

  • FDA GLP-1

    FDA · Checked